When Recurrent Myxoma Is Not a Myxoma Authors: Júlia Fernandes Aguiar, Bruno Mahler Mioto Published: 2026 ABSTRACT Corresponding Author Primary cardiac tumor detection has increased substantially over the past decade, driven by the widespread adoption and improved sensitivity of multimodality imaging.1 Although 75% to 90% of these masses are benign, their clinical significance is determined not only by histology but also by anatomical location, risk of intracardiac obstruction, valvular dysfunction, arrhythmia, and embolic potential.2 Malignant tumors comprise the remaining 10% to 25%; within this group, precise histopathological classification is essential as prognosis and therapeutic strategies differ profoundly across subtypes. Angiosarcoma remains the most common primary cardiac malignancy, followed by rhabdomyosarcoma, malignant mesothelioma, and fibrosarcoma.1,2 Among these rare tumors, cardiac myxofibrosarcoma (MFS) represents an exceptionally uncommon yet clinically important entity. Despite accounting for fewer than 5% of primary cardiac sarcomas, MFS carries a marked propensity for local recurrence, infiltrative growth, and diagnostic misclassification. Its ability to mimic benign cardiac myxoma both clinically and morphologically renders delayed or incorrect diagnosis not merely an academic concern but a determinant of oncological outcome.3 In this issue of JACC: Case Reports, Watanabe et al4 describe a compelling example of this diagnostic challenge. A 31-week pregnant woman presented with acute heart failure caused by 2 large left atrial masses prolapsing through the mitral valve, 3 years after resection of a left atrial tumor initially diagnosed as myxoma. After redo surgical resection, retrospective pathological review of the original and recurrent specimens demonstrated findings consistent with MFS rather than benign myxoma. The implication is important: this was not a malignant transformation of a benign lesion but most likely an initial diagnostic misclassification.4 Distinguishing cardiac myxoma from MFS remains challenging, as both tumors frequently arise in the left atrium and may appear gelatinous, mobile, and polypoid on imaging.3,5 Transthoracic echocardiography provides excellent sensitivity for detecting intracardiac masses; however, its capacity to differentiate benign from malignant myxoid tumors is suboptimal.2 Cardiac computed tomography improves anatomical definition and surgical planning, whereas cardiac magnetic resonance offers superior tissue characterization, particularly for identifying necrosis, hemorrhage, and infiltrative features suggestive of malignancy.6 Characteristically, MFS demonstrates heterogeneous gadolinium enhancement and T2-weighted hypersignal, reflecting its complex internal architecture. Positron emission tomography with 18F-fluorodeoxyglucose complements morphological assessment by quantifying metabolic activity, thereby facilitating systemic staging and supporting malignant stratification.5 Yet even with advanced multimodality imaging, no single modality reliably distinguishes MFS from myxoma with pathological certainty. Ultimately, definitive diagnosis depends on histopathological and immunohistochemical evaluation.7 Histologically, MFS is characterized by increased cellularity, spindle or stellate cell morphology, nuclear atypia, curvilinear vasculature, and a myxoid stroma. Additional features favoring malignancy include infiltrative growth, coagulative necrosis, and brisk mitotic activity. Immunohistochemistry is indispensable in this differential. Calretinin expression consistently supports cardiac myxoma, whereas its absence constitutes a primary argument against a benign myxomatous lesion. Concurrently, a high proliferative index, assessed by Ki-67 or MIB-1 staining, corroborates sarcomatous behavior.3,7 In the case presented by Watanabe et al, the recurrent tumor demonstrated calretinin negativity in conjunction with an MIB-1 hot spot index of 40%. Importantly, retrospective review of the original specimen revealed a similarly elevated proliferative index of approximately 30%, along with brisk mitotic activity of 3 to 5 mitoses per high-power field. These findings strongly support that the original lesion already represented MFS at the time of first resection.4 One of the most clinically relevant distinctions between cardiac myxoma and MFS lies in recurrence behavior. Sporadic cardiac myxoma rarely recurs after complete resection and generally follows an indolent course. MFS, by contrast, demonstrates infiltrative growth along myocardial planes and carries a substantial risk of local recurrence even after apparently complete surgical excision, a biological reality that reflects the difficulty of achieving true oncological margins in a cardiac surgical field. In the pooled analysis by Sun et al,3 recurrence frequently occurred within months despite aggressive resection. This biological behavior has direct practical implications. Apparent “recurrent myxoma,” particularly when associated with rapid regrowth, infiltrative characteristics, multifocal disease, or valvular involvement, should immediately suspend the presumption of benignity and trigger pathological re-evaluation with comprehensive immunohistochemical analysis (Figure 1).3,7Figure 1Diagnostic Re-Evaluation of Recurrent Apparent Cardiac Myxoma Leading to Reclassification as Cardiac MyxofibrosarcomaThe figure summarizes the clinical presentation, multimodality imaging findings, histopathological characteristics, and recurrence pattern supporting distinction between benign cardiac myxoma and cardiac myxofibrosarcoma. Recurrent disease, infiltrative behavior, heterogeneous imaging features, and high proliferative activity should prompt histopathological re-evaluation for malignant mimics, particularly myxofibrosarcoma. CT = computed tomography; MRI = magnetic resonance imaging. Diagnostic Re-Evaluation of Recurrent Apparent Cardiac Myxoma Leading to Reclassification as Cardiac Myxofibrosarcoma The figure summarizes the clinical presentation, multimodality imaging findings, histopathological characteristics, and recurrence pattern supporting distinction between benign cardiac myxoma and cardiac myxofibrosarcoma. Recurrent disease, infiltrative behavior, heterogeneous imaging features, and high proliferative activity should prompt histopathological re-evaluation for malignant mimics, particularly myxofibrosarcoma. CT = computed tomography; MRI = magnetic resonance imaging. Beyond its pathological implications, the report by Watanabe et al underscores the complexity of decision making in cardiovascular disease during pregnancy. The authors used a staged strategy consisting of intra-aortic balloon pump support, cesarean delivery, and redo cardiac surgery in a patient with impending hemodynamic collapse, achieving maternal survival and fetal viability without compromising oncological urgency. This approach exemplifies the increasingly multidisciplinary nature of contemporary cardio-obstetric care and is consistent with the 2025 European Society of Cardiology guidelines, which recommend delivery before maternal cardiac surgery when fetal viability has been established.8 What this case ultimately reveals is that MFS does not announce itself; it conceals behind a more familiar diagnosis, only to return with greater consequence. The obligation of the clinician and pathologist, then, is not to wait for that return but to anticipate it: through systematic histopathological evaluation, standardized immunohistochemical protocols, and a sustained willingness to question a diagnosis that recurs where recurrence should be rare. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.